Gai Wenbin, Peng Zhiqiang, Liu Cui Hua, Zhang Lingqiang, Jiang Hong
Department of Physiology, Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders and State Key Disciplines: Physiology, School of Basic Medicine, Medical College, Qingdao University, Qingdao, China.
State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.
Front Cell Dev Biol. 2021 Apr 8;9:653882. doi: 10.3389/fcell.2021.653882. eCollection 2021.
Developmental down-regulation protein 8 (NEDD8), expressed by neural progenitors, is a ubiquitin-like protein that conjugates to and regulates the biological function of its substrates. The main target of NEDD8 is cullin-RING E3 ligases. Upregulation of the neddylation pathway is closely associated with the progression of various tumors, and MLN4924, which inhibits NEDD8-activating enzyme (NAE), is a promising new antitumor compound for combination therapy. Here, we summarize the latest progress in anticancer strategies targeting the neddylation pathway and their combined applications, providing a theoretical reference for developing antitumor drugs and combination therapies.
由神经祖细胞表达的发育下调蛋白8（NEDD8）是一种类泛素蛋白，它与底物结合并调节其生物学功能。NEDD8的主要靶标是cullin-RING E3连接酶。NEDD8化途径的上调与各种肿瘤的进展密切相关，而抑制NEDD8激活酶（NAE）的MLN4924是一种有前景的新型抗肿瘤化合物，可用于联合治疗。在此，我们总结了针对NEDD8化途径的抗癌策略及其联合应用的最新进展，为开发抗肿瘤药物和联合治疗提供理论参考。
